Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bispecific antibodies
Pharma
FDA slams China-heavy data in Summit’s ivonescimab CRL
FDA reviewers also flagged concerns over the geographic makeup of Summit’s HARMONi trial, noting that 93% of the PFS events occurred in China.
Angus Liu
Nov 17, 2026 4:48pm
FDA rejects Summit’s PD-1xVEGF ivonescimab in NSCLC
Nov 15, 2026 7:50am
BioNTech pays $205M for FDA voucher to speed up cancer pipeline
Nov 11, 2026 8:20am
For Merck, 2027 is ‘another year of investment’
Oct 29, 2026 11:23am
Fierce Biotech
After Enhertu: The slow hunt for next-gen HER2 breast cancer drugs
Oct 28, 2026 9:00am
Akeso CEO looks for more ivonescimab combos after AZ deal
Oct 25, 2026 11:30am